Conservative Surgery of Renal Carcinoma: The EIRSS Experience

Authors

  • M. MARBERGRE,

    Urologist-in-Chief, Corresponding author
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. Krankcnanstalt Rudolfstiftung, Vienna, Austria (formerly at Department of Urology, University of Mainz Medical School, FRG)
      *Department of Urology, Krankenanstalt Rudolfstiflung, Juchgasse 25, A-1030 Vienna, Austria
    Search for more papers by this author
  • R. C. B. PUGH,

    Consultant Pathologist
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. St Peter's Hospitals, London
    Search for more papers by this author
  • J. AUVERT,

    Professor of Urology
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. Hôpital Henri Mondor, 94010 Créteil, France
    Search for more papers by this author
  • H. BERTERMANN,

    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. Department of Urology, Universitäts-kliniken Kiel, FRG
    Search for more papers by this author
  • A. COSTANTINI,

    Professor of lirology
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. Univcrsità degli Studi, Florence, Italy
    Search for more papers by this author
  • P. A. GAMMELGAARD,

    Professor
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. Københavns Amts Sygehus i Herlev, 2710 Herlev, Denmark
    Search for more papers by this author
  • S. PETTERSON,

    Surgeon-in-Chief
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. Sahlgrenska Sjukhuset, 413 45 Gothenburg, Sweden
    Search for more papers by this author
  • J. E. A. WICKHAM

    Urologist-in-Chief
    1. Departments of Urology: Rudolfstiftung, Vienna, Austria; Universitätskliniken Mainz, FRG; Hôpital Henri Mondor, Créteil, France; Universitätskliniken Kiel, FRG; Universita degli Studi, Florence, Italy; Københavens Amts Sygehus i Herlev, Denmark; Sahlgrenska Sjukhuset, Gothenburg, Sweden; St Peter's Hospitals, London and Department of Pathology, St Peter's Hospitals, London
    2. St Peter's Hospitals and St Bartholomew's Hospital, London
    Search for more papers by this author

*Department of Urology, Krankenanstalt Rudolfstiflung, Juchgasse 25, A-1030 Vienna, Austria

Abstract

Summary— Seventy-two patients with renal carcinoma (RC) in a solitary kidney or bilateral synchronous tumours underwent parenchyma-sparing excision of their neoplasms. This was performed in situin 51 and extracorporeally in 21 kidneys, with a complication rate respectively of 1 7 and 43%. The 5-year survival rates were 78% for unilateral disease, 48% for bilateral synchronous and 38% for bilateral asynchronous disease.

Survival correlated with Pcategory, grade and diameter of the tumour. Vascular invasion and spindle cells indicated a poor prognosis; the position of the tumour, oncocytic elements, calcification, lymphocytic infiltration or the predominance of clear cell or granular cells did not influence survival.

Ancillary